Rossari Biotech Ltd
P&L
Quarterly Consolidated
vs Q1 FY26
Rossari Biotech Announces Q2 FY26 Results: Revenues at Rs. 586.1 Cr, up 18% YoY
16 Oct 2025 · 16 Oct 2025, 04:52 pm
Summary
Rossari Biotech Limited, a Specialty-Chemicals manufacturer, has announced its financial results for the quarter ended September 30, 2025. The company reported a 18% YoY growth in revenue, 9% YoY growth in EBITDA, and 5% YoY growth in PAT.
Key Highlights
- 1
Q2 FY26 Revenues at Rs. 586.1 Cr, up 18% YoY
- 2
EBITDA at Rs. 71.9 Cr, up 9% YoY
- 3
PAT at Rs. 36.9 Cr, up 5% YoY
- 4
H1 FY26 Revenue from operations stood at Rs. 1,129.8 crore, up 14%
- 5
Exports grew by 36% YoY in Q2 FY26 and 27% in H1 FY26
- 6
Additional 20,000 MTPA capacity commissioned at Dahej facility
- 7
15,000 MTPA ethoxylation capacity commissioned at Unitop
- 8
Board approved an investment of up to USD ~8 million in Rossari International Limited Company
Management Comments
Mr. Edward Menezes
Promoter & Executive Chairman, and Mr. Sunil Chari, Promoter & Managing Director
We delivered healthy revenue growth of 18% YoY in Q2 FY26, led by broad-based volume expansion across our key segments... We are confident that as these initiatives begin to contribute to revenues, profitability will improve progressively going forward... As a growth-focused Company, we remain committed to innovation, continuously developing tailored solutions that meet the evolving needs of our customers... We are working towards expanding our global footprint through our own manufacturing set up and sales & distribution network overseas.
Informational and educational content only. Not investment advice.